NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX ). Such investors are advised ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

2-Year U.S. Treasury Note Continuous Contract $103.035-0.023-0.02% 5-Year U.S. Treasury Note Continuous Contract $107.273-0.070-0.07% 10-Year U.S. Treasury Note Continuous Contract $110.391-0.125 ...

2-Year U.S. Treasury Note Continuous Contract $103.063 0.004 0.00% 5-Year U.S. Treasury Note Continuous Contract $107.375 0.031 0.03% 10-Year U.S. Treasury Note Continuous Contract $110.563 0.047 ...